Cell Analysis Technology Platform

Circulating Tumor Cell platform

Circulating Tumor Cell (CTC), detach from the solid tumor to blood circulation, which was first observed by Aust Med J Ashworth etc in metastatic cancer patients’ blood.

In recent years, with the development of research methodology, CTC has been detected in the patients’blood with lung cancer, breast cancer, prostate ccolorectal cancer, bladder cancer, ovarian cancer and other malignant tumor, which are closely related with the patient's clinical staging, progression-free survival, overall survival, drug efficacy, early recurrence and metastasis.  CTC detection belong to "liquid biopsy” , is a new way in cancer screening, treatment real-time monitoring, prognosis evaluation, cancer recurrence prediction, drug resistance analysis, auxiliary diagnosis and clinical process. CTC detection not only make up the deficiency of the existing clinical tumor diagnosis methods, also provides the clinical analysis platform of tumor cells from cell to molecular level, and information for individualized treatment. Because the  significance of the CTC detection in the clinical, our company  has carried out iFISH-CTC and Cell Search technical platform to test the CTC.

Clinical application and research significance of IFISH-CTC and Cell Search detection.

(1)progression-free surial (PFS) and overall survival (OS) research based on CTC 

  Whether before or after the treatment, CTC is a strong independent predictor. Clinical research has proved that when the CTC in the blood is higher than the threshold (cut off) , the prognosis is not good, and when CTC of the sample is lower than the threshold (cut off) that indicate good prognosis.

(2) Evaluae the curative effect, develop individualized treatment

CTC as an independent prognostic factor can reflect the status of treatment during the process, the CTC number increase indicate that curative effect is not good, and reduce mean that curative effect is good. The real-time, sensitive, reliable method can help doctors to correctly judge the curative effect and develop effective individualized treatment.

(3)CTC detection is earlier, more accurate and more sensitive than imaging and other biomarkers in judging the curative effect and prognosis

CTC detection can be earlier, more accurate, more sensitive than traditional imaging in judging prognosis. Many studies have shown that: the results of CTC at 4 weeks after treatment for prognostic match the traditional imaging at 12 weeks after treatment. Moreover, when the CTC value is  equal or greater than the threshold (cut-off), CTC detection is more accurate than imaging for prognosis judgment.

CTC detection is better than biomarkers to judge the curative effect and prognosis. Researches show that: CTC detection as prognostic marker is more accurate and sensitive than traditional PSA in prostate cancer.

(4)CTC detection has important significance in the early diagnosis of tumors

Tumor patients have clinical symptoms when the tumor is generally in advanced stage, and CTC detection can detect the early tumor, which can be help for treatment and prevention of tumor.

(5) Real-time monitoring of disease progression

Compared between CTC detection before and after treatment, which can realize the real-time monitoring of therapeutic effect and effective assessment. Real-time monitoring of tumor drug resistance can be detected at the same time. In addition, CTC detection can be used to predict the patient's survival.

(6)Single-celled sequencing of Circulating tumor cells

For advanced or non-surgical patients are difficult to obtain sufficient tissue samples and unable to real-time monitor, which restrict the use of targeted drugs. CTC as alternative sources of specimen, can reflect the information of tumor progression, which can realize real-time monitoring of mutations in tumor gene expression / mutation.

CTC sequencing technology can be used for detection of differences in gene expression patterns, identifying new CTC candidate biomarkers. In addition, through the CTC sequencing of exome, whole genome sequencing and the cells copy number variations, can monitor the tumor metastasis. Single CTC spectral analysis for different patients, can be used for identification and classification  of pathological subtype mode.

FISH platform

1、Clinical and scientific research applications:

a.Application of tumor classification

Main application scope: early prevention and treatment, auxiliary clinical medical diagnosis, assessment of tumor prognosis, the median survival, medication guide and treatment.

b.Application in leukemia classification

Leukemia may related to the lack, translocation and rearrangement of specific locus on chromosome fragment. Different types of leukemia have different mechanism and the relevant treatment. So accurate leukemia classification is important for the corresponding treatment.The main diagnostic methods is fluorescence in situ hybridization technique.

2、Technical parameters

1)High specificity, probe length between 1Kb-4Mb, FISH probe can specificity to identify the genes and fragments of chromosome.

2)Good stability, invariance after the processing of in situ hybridization, and can be used in two years after a tag

3)High sensitivity, positioning DNA sequence length about 1 Kb.

4)Objective, results of fluorescence in situ hybridization is determinated by the color and signal counts of the fluorescent, objectively quantify the detection results.

5)Good repeatability.

Karyotyping platform

1.Clinical and scientific research applications:

a)Detection of chromosomal abnormalities is helpful to the diagnosis and classification of hemopathy.

b)Karyotype analysis can be used for remission and recurrence monitoring of leukemia.

c)Chromosome as independent prognostic indicators help the choice of treatment.

d)Chromosome preparation for chromosome fluorescent in situ hybridization technique can improve the sensitivity, accuracy and reliability of karyotype analysis.

2.Technical parameters:

Low cost, large flux, analysis one or unknown chromosome mutations of the 46 chromosomes on the macro.

Low resolution: can only detect more than 5-10Mb large fragment missing or duplicate

  • Contact Us
  • Shanghai Biotecan Pharmaceuticals Co., Ltd.
  • Telephone:+86-21-50277725
  • Address

    First Shanghai Centre, 180 Zhangheng Rd., Pudong New District, Shanghai, China

Copyright © 2015-2018 Shanghai Biotecan Pharmaceuticals Co., Ltd. All Rights Reserved 沪ICP备09055310号-1 沪公网安备 31011502003232号